Abstract P4-02-13: Inter- and intra-laboratory variation in grading of invasive breast cancer: A nationwide study in the Netherlands

2019 ◽  
Author(s):  
C van Dooijeweert ◽  
PJ van Diest ◽  
SM Willems ◽  
CC Kuijpers ◽  
LI Overbeek ◽  
...  
Keyword(s):  
Breast Cancer ◽  
The Netherlands ◽  
Invasive Breast Cancer ◽  
Nationwide Study

scholarly journals Significant inter‐ and intra‐laboratory variation in grading of invasive breast cancer: A nationwide study of 33,043 patients in the Netherlands

2019 ◽  
Vol 146 (3) ◽  
pp. 769-780 ◽  
Author(s):  
Carmen Dooijeweert ◽  
Paul J. Diest ◽  
Stefan M. Willems ◽  
Chantal C. H. J. Kuijpers ◽  
Elsken Wall ◽  
...  
Keyword(s):  
Breast Cancer ◽  
The Netherlands ◽  
Invasive Breast Cancer ◽  
Nationwide Study

scholarly journals The effect of breast MRI on disease-free and overall survival in breast cancer patients: a retrospective population-based study

2020 ◽  
Vol 184 (3) ◽  
pp. 951-963
Author(s):  
T. J. A. van Nijnatten ◽  
L. P. T. van Tiel ◽  
A. C. Voogd ◽  
C. G. M. Groothuis-Oudshoorn ◽  
S. Siesling ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Regression Analysis ◽  
The Netherlands ◽  
Invasive Breast Cancer ◽  
Invasive Carcinoma ◽  
Cox Regression ◽  
Breast Mri ◽  
Histological Subtypes ◽  
Disease Free

Abstract Purpose To evaluate the effect of breast MRI on overall survival (OS) and disease-free survival (DFS) of patients with invasive breast cancer in the Netherlands. Methods We selected all women from the Netherlands Cancer Registry diagnosed with invasive breast cancer (a) between 2011 and 2013 for the OS-cohort and (b) in the first quarter of 2012 for the DFS-cohort. The study population was subdivided into an MRI and non-MRI group. In addition, subgroups were created according to breast cancer subtype: invasive carcinoma of no special type (NST) versus invasive lobular carcinoma (ILC). OS and DFS were compared between the MRI and non-MRI group using the Kaplan–Meier method and the log-rank test. Cox proportional hazard regression analysis was performed to estimate hazard ratios (HR) with a 95% confidence interval (CI). To account for missing data, multiple imputation was performed. Results Of the 31,756 patients included in the OS-cohort (70% non-MRI and 30% MRI), 27,752 (87%) were diagnosed with invasive carcinoma NST and 4004 (13%) with ILC. Of the 2464 patients included in the DFS-cohort (72% non-MRI and 28% MRI), 2161 (88%) were diagnosed with invasive carcinoma NST and 303 (12%) with ILC. The distribution of breast MRI use was significantly lower over different age categories, from 49.0% aged < 50 to 16.5% aged > 70. Multivariable Cox regression showed that breast MRI was not significantly associated with OS overall (HR 0.91, 95%-CI 0.74–1.11, p = 0.35), nor in the different histological subtypes. Multivariable Cox regression analysis showed that breast MRI was also not significantly associated with DFS (HR 1.16, 95%-CI 0.81–1.67), nor in the different histological subtypes. Conclusion Use of breast MRI was not significantly associated with an improved OS or DFS in patients treated with primary surgery.

scholarly journals Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands

BMJ ◽  
2019 ◽  
pp. l1652 ◽  
Author(s):  
Christel J M de Blok ◽  
Chantal M Wiepjes ◽  
Nienke M Nota ◽  
Klaartje van Engelen ◽  
Muriel A Adank ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
The Netherlands ◽  
Confidence Interval ◽  
Invasive Breast Cancer ◽  
Hormone Treatment ◽  
Transgender People ◽  
Trans Men ◽  
In Trans ◽  
Trans Women

AbstractObjectiveTo investigate the incidence and characteristics of breast cancer in transgender people in the Netherlands compared with the general Dutch population.DesignRetrospective, nationwide cohort study.SettingSpecialised tertiary gender clinic in Amsterdam, the Netherlands.Participants2260 adult trans women (male sex assigned at birth, female gender identity) and 1229 adult trans men (female sex assigned at birth, male gender identity) who received gender affirming hormone treatment.Main outcome measuresIncidence and characteristics (eg, histology, hormone receptor status) of breast cancer in transgender people.ResultsThe total person time in this cohort was 33 991 years for trans women and 14 883 years for trans men. In the 2260 trans women in the cohort, 15 cases of invasive breast cancer were identified (median duration of hormone treatment 18 years, range 7-37 years). This was 46-fold higher than in cisgender men (standardised incidence ratio 46.7, 95% confidence interval 27.2 to 75.4) but lower than in cisgender women (0.3, 0.2 to 0.4). Most tumours were of ductal origin and oestrogen and progesterone receptor positive, and 8.3% were human epidermal growth factor 2 (HER2) positive. In 1229 trans men, four cases of invasive breast cancer were identified (median duration of hormone treatment 15 years, range 2-17 years). This was lower than expected compared with cisgender women (standardised incidence ratio 0.2, 95% confidence interval 0.1 to 0.5).ConclusionsThis study showed an increased risk of breast cancer in trans women compared with cisgender men, and a lower risk in trans men compared with cisgender women. In trans women, the risk of breast cancer increased during a relatively short duration of hormone treatment and the characteristics of the breast cancer resembled a more female pattern. These results suggest that breast cancer screening guidelines for cisgender people are sufficient for transgender people using hormone treatment.

Sign in / Sign up

Export Citation Format

Share Document